Nuvation Bio (NASDAQ: NUVB) awards 123,397 stock options to director

Rhea-AI Filing Summary

Nuvation Bio Inc. reported that director Kim D. Blickenstaff received a grant of stock options. The award covers 123,397 options to buy Class A common stock at an exercise price of $4.79 per share, expiring on May 20, 2036.

All of the options vest 100% on the earlier of May 21, 2026 or the next shareholder annual meeting, as long as the director remains in continuous service. Following this grant, the filing shows 123,397 derivative securities held directly, with no open‑market purchases or sales reported.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BLICKENSTAFF KIM D

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	123,397	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 123,397 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 123,397 options Exercise price: $4.79 per share Options after transaction: 123,397 derivative securities +2 more

5 metrics

Option grant size 123,397 options Stock Option (Right to Buy) granted to director on May 21, 2026 filing date reference

Exercise price $4.79 per share Conversion or exercise price for Class A common stock options

Options after transaction 123,397 derivative securities Total options held following the grant transaction

Option expiration May 20, 2036 Expiration date of the stock option award

Cliff vesting date May 21, 2026 100% vesting on earlier of this date or next annual meeting

Key Terms

Stock Option (Right to Buy), Class A Common Stock, derivative securities, vesting

4 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

Class A Common Stock financial

"underlying_security_title": "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

derivative securities financial

"total_shares_following_transaction": "123397.0000""

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

vesting financial

"100% of the shares subject to the option shall vest on the earlier of"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BLICKENSTAFF KIM D

(Last) (First) (Middle)

C/O NUVATION BIO INC.

1500 BROADWAY, SUITE 1401

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.79	05/21/2026		A		123,397		(1)	05/20/2036	Class A Common Stock	123,397	$0	123,397	D

Explanation of Responses:

1. 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.

	/s/ Stephen Dang, Attorney-in-Fact	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Nuvation Bio (NUVB) report for Kim D. Blickenstaff?

Nuvation Bio reported a grant of stock options to director Kim D. Blickenstaff for 123,397 shares of Class A common stock. This is a compensation-related award, not an open-market purchase or sale of existing shares.

How many Nuvation Bio (NUVB) options were granted and at what price?

The filing shows 123,397 stock options granted with an exercise price of $4.79 per share. These options give the director the right to buy Nuvation Bio Class A common stock at that fixed price in the future.

When do the newly granted Nuvation Bio (NUVB) options vest?

All granted options vest 100% on the earlier of May 21, 2026, or the next shareholder annual meeting. Vesting is conditioned on Kim D. Blickenstaff maintaining continuous service with Nuvation Bio through the applicable vesting date.

Did the Nuvation Bio (NUVB) Form 4 show any stock sales or purchases?

The Form 4 reports an acquisition of stock options as a grant or award and no open-market purchases or sales. It records one derivative transaction, increasing the director’s option holdings without changing common shares held through market trading.

What is the expiration date of the Nuvation Bio (NUVB) options granted?

The granted stock options expire on May 20, 2036, according to the Form 4. After this expiration date, any unexercised options will lapse and no longer give the right to buy Nuvation Bio Class A common stock at $4.79.